Virios Therapeutics, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. MacroGenics Gets $40m Up Front For St

Tonix Pharmaceuticals Holding Corp. ’s Phase II PREVAIL study of TNX-102 SL in long COVID missed its primary endpoint of pain, but it showed a positive signal on the key secondary endpoint – and much

Virios Therapeutics, Inc. thinks COVID-19 could have thwarted a Phase IIb trial testing its lead drug candidate, a fixed-dose combination of the antiviral famciclovir and non-steroidal anti-inflammat

Fully two years into the COVID-19 pandemic, biopharmaceutical companies and academic/non-profit research organizations continue to partner on efforts to prevent and combat infections by the SARS-CoV-2